Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 34th Annual J.P. Morgan Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 4:30 p.m. PT (7:30 p.m. ET) on Wednesday, January 13, 2016 in San Francisco.
A live audio webcast and archive of the presentation will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
CONTACTS: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 [email protected] Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 [email protected]
